Nanotechnology Now

Our NanoNews Digest Sponsors

Heifer International

Wikipedia Affiliate Button

Home > Press > Stephen Gracon, D.V.M., Joins the NanoBio Team as Vice President of Regulatory Affairs

Abstract:
NanoBio(R) Corporation, a biopharmaceutical company focused on developing and commercializing novel products for the prevention and treatment of infectious diseases, today announced the addition of Stephen Gracon, D.V.M., as Vice President of Regulatory Affairs.

Stephen Gracon, D.V.M., Joins the NanoBio Team as Vice President of Regulatory Affairs

ANN ARBOR, MI | Posted on January 16th, 2008

In his new role, Dr. Gracon will lead the regulatory and quality assurance activities for the company's rich pipeline of anti-infective products and mucosal vaccines.

Dr. Gracon brings 30 years of experience to NanoBio in diverse areas within the pharmaceutical industry, including pathology and experimental toxicology, clinical research, and regulatory affairs within the United States and internationally. Dr. Gracon served in various clinical, research and regulatory positions at Parke-Davis, Pfizer, Amgen and Baxter prior to joining NanoBio. He has a unique combination of experience with both small and large molecules in a broad range of indications, as well as with seasonal and pandemic vaccines and plasma-derived products.

"NanoBio's platform is very unique and has tremendous potential far beyond the current indications under investigation," said Dr. Gracon. "My role is to develop and execute strategies with the NanoBio team to navigate and expedite the FDA approval process for the numerous topical agents and vaccines that can be developed from our proprietary nanotechnology platform."

"We are very fortunate to have Dr. Gracon's extensive regulatory experience as we prepare for multiple regulatory submissions," added James Baker Jr., M.D., founder and CSO of NanoBio Corporation. "His specialized knowledge of regulatory protocol for both therapeutics and vaccines will be critical to moving NanoBio's products to FDA approval."

####

About NanoBio Corporation
NanoBio(R) Corporation is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company's headquarters and laboratory facilities are located in Ann Arbor, Mich.

For more information, please click here

Contacts:
NanoBioŽ Corporation

2311 Green Road, Suite A
Ann Arbor, Michigan 48105
Telephone:734.302.4000
Fax:734.302.9150
V.P. Business Development:
John Coffey (Ext. 107)

Copyright © PR Newswire Association LLC.

If you have a comment, please Contact us.

Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.

Bookmark:
Delicious Digg Newsvine Google Yahoo Reddit Magnoliacom Furl Facebook

Related News Press

News and information

Freeze-dried foam soaks up carbon dioxide: Rice University scientists lead effort to make novel 3-D material August 16th, 2017

Gold shines through properties of nano biosensors: Researchers discover that fluorescence in ligand-protected gold nanoclusters is an intrinsic property of the gold particles themselves August 16th, 2017

Two Scientists Receive Grants to Develop New Materials: Chad Mirkin and Monica Olvera de la Cruz recognized by Sherman Fairchild Foundation August 16th, 2017

Scientists from the University of Manchester and Diamond Light Source work with Deben to develop and test a new compression stage to study irradiated graphite at elevated temperatures August 15th, 2017

Nanomedicine

Freeze-dried foam soaks up carbon dioxide: Rice University scientists lead effort to make novel 3-D material August 16th, 2017

Gold shines through properties of nano biosensors: Researchers discover that fluorescence in ligand-protected gold nanoclusters is an intrinsic property of the gold particles themselves August 16th, 2017

Two Scientists Receive Grants to Develop New Materials: Chad Mirkin and Monica Olvera de la Cruz recognized by Sherman Fairchild Foundation August 16th, 2017

JPK reports on how the University of Glasgow is using their NanoWizardŽ AFM and CellHesion module to study how cells interact with their surroundings August 2nd, 2017

Announcements

Freeze-dried foam soaks up carbon dioxide: Rice University scientists lead effort to make novel 3-D material August 16th, 2017

Gold shines through properties of nano biosensors: Researchers discover that fluorescence in ligand-protected gold nanoclusters is an intrinsic property of the gold particles themselves August 16th, 2017

Two Scientists Receive Grants to Develop New Materials: Chad Mirkin and Monica Olvera de la Cruz recognized by Sherman Fairchild Foundation August 16th, 2017

Scientists from the University of Manchester and Diamond Light Source work with Deben to develop and test a new compression stage to study irradiated graphite at elevated temperatures August 15th, 2017

Appointments/Promotions/New hires/Resignations/Deaths

180 Degree Capital Corp. Appoints Investment Banking Veteran Parker Weil to Its Board of Directors August 2nd, 2017

Nanometrics Announces Retirement Plans of CEO Timothy Stultz: Dr. Stultz to Continue as Director May 25th, 2017

180 Degree Capital Corp. Announces the Start of Kevin Rendino as Chairman and Chief Executive Officer and Completion of its Transition to a Registered Closed-End Fund March 31st, 2017

Francis Alexander Named Deputy Director of Brookhaven Lab's Computational Science Initiative February 16th, 2017

NanoNews-Digest
The latest news from around the world, FREE



  Premium Products
NanoNews-Custom
Only the news you want to read!
 Learn More
NanoTech-Transfer
University Technology Transfer & Patents
 Learn More
NanoStrategies
Full-service, expert consulting
 Learn More











ASP
Nanotechnology Now Featured Books




NNN

The Hunger Project